Makhoul et al. showed that FGF2 rs1960669 was associated with a pathologic complete response in their prospective phase II study of the use of BVZ as neoadjuvant to chemotherapy in breast cancer patients [24]. The gene discussed is FGF2; the disease is breast carcinoma.